Pemigatinib and Retifanlimab for Advanced Liposarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests two experimental drugs (pemigatinib and retifanlimab) for advanced dedifferentiated liposarcoma that has not responded to other treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You need a confirmed diagnosis of dedifferentiated liposarcoma with specific MDM2 gene changes
- Your cancer must have gotten worse or come back after at least one previous treatment, or you cannot have standard chemotherapy for medical reasons
- You must be able to swallow pills and have a tumor that can be measured on a CT scan
- You should be in generally good health (able to do daily activities) and have normal organ function based on blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
This trial tests a first-line treatment for people with advanced or unresectable dedifferentiated liposarcoma that has spread. The goal is to find a therapy that works before other treatments are used.
This trial tests a combination of the targeted drug abemaciclib and radiation therapy before surgery for people with a specific type of liposarcoma. The goal is to see if this combination can shrink the tumor and help make surgery more effective.
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
This study looks at how well standard treatments work for people whose liposarcoma has come back in the same area. It helps doctors understand best ways to manage this rare cancer.
Hear when a new Dedifferentiated Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.